UBS lowered the firm’s price target on Rapt Therapeutics (RAPT) to $1 from $2 and keeps a Neutral rating on the shares. UBS believes think Rapt’s RPT904 omalizumab “bio-better” in-licensing is key for the pipeline, although this is a longer-term story, the analyst tells investors in a research note. The firm sees food allergy as a large market, although it is currently difficult to define the exact addressable population where ‘904 will have clinically meaningful efficacy.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RAPT:
- Rapt Therapeutics assumed with a Buy at H.C. Wainwright
- RAPT Therapeutics: Promising Clinical Developments and Strong Financial Performance Justify Buy Rating
- RAPT Therapeutics Reports Improved Q1 2025 Results
- Rapt Therapeutics reports Q1 EPS (8c), consensus (14c)
- Rapt Therapeutics appoints Jessica Savage as VP, clinical development